Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.

Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, Eisenwiener K, Beglinger C, Mäcke HR.

Int J Cancer. 2002 Apr 20;98(6):930-7.

2.

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors.

Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, Reubi JC, Mäcke HR.

Bioconjug Chem. 2002 May-Jun;13(3):530-41.

PMID:
12009943
3.

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.

Froidevaux S, Heppeler A, Eberle AN, Meier AM, Häusler M, Beglinger C, Béhé M, Powell P, Mäcke HR.

Endocrinology. 2000 Sep;141(9):3304-12.

PMID:
10965902
4.

Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR.

Clin Cancer Res. 2005 Feb 1;11(3):1136-45.

5.
6.

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC.

Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47. Epub 2003 Aug 21.

PMID:
12937948
8.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP.

Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. doi: 10.1677/ERC-09-0078. Print 2010 Mar. Review.

PMID:
19995807
9.

Design, Synthesis, and Biological Evaluation of 68Ga-DOTA-PA1 for Lung Cancer: A Novel PET Tracer for Multiple Somatostatin Receptor Imaging.

Liu F, Liu T, Xu X, Guo X, Li N, Xiong C, Li C, Zhu H, Yang Z.

Mol Pharm. 2018 Feb 5;15(2):619-628. doi: 10.1021/acs.molpharmaceut.7b00963. Epub 2018 Jan 19.

PMID:
29278911
10.

Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18.

PMID:
22918768
11.

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H.

Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):982-93. Epub 2007 Jan 16.

PMID:
17225119
12.

Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.

Zhang L, Vines DC, Scollard DA, McKee T, Komal T, Ganguly M, Do T, Wu B, Alexander N, Vali R, Shammas A, Besanger T, Baruchel S.

Contrast Media Mol Imaging. 2017 Aug 8;2017:9481276. doi: 10.1155/2017/9481276. eCollection 2017.

13.

Preliminary PET/CT Imaging with Somatostatin Analogs [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC.

Satpati D, Shinto A, Kamaleshwaran KK, Sarma HD, Dash A.

Mol Imaging Biol. 2017 Dec;19(6):878-884. doi: 10.1007/s11307-017-1072-z.

PMID:
28349291
14.

Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.

Ishizaki A, Mishiro K, Shiba K, Hanaoka H, Kinuya S, Odani A, Ogawa K.

Ann Nucl Med. 2019 Apr;33(4):244-251. doi: 10.1007/s12149-018-01326-5. Epub 2019 Jan 3.

PMID:
30604401
15.

Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.

Petersen AL, Binderup T, Jølck RI, Rasmussen P, Henriksen JR, Pfeifer AK, Kjær A, Andresen TL.

J Control Release. 2012 Jun 10;160(2):254-63. doi: 10.1016/j.jconrel.2011.12.038. Epub 2012 Jan 5.

PMID:
22245688
16.

In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.

Niedermoser S, Chin J, Wängler C, Kostikov A, Bernard-Gauthier V, Vogler N, Soucy JP, McEwan AJ, Schirrmacher R, Wängler B.

J Nucl Med. 2015 Jul;56(7):1100-5. doi: 10.2967/jnumed.114.149583. Epub 2015 May 14.

17.

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.

Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ.

Bioconjug Chem. 2002 Jul-Aug;13(4):721-8.

PMID:
12121126
18.

Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.

Fani M, Mueller A, Tamma ML, Nicolas G, Rink HR, Cescato R, Reubi JC, Maecke HR.

J Nucl Med. 2010 Nov;51(11):1771-9. doi: 10.2967/jnumed.110.076695. Epub 2010 Oct 18.

19.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.

Semin Nucl Med. 2002 Apr;32(2):133-40. Review.

PMID:
11965608
20.

[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.

Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA.

Eur J Med Chem. 2014 Feb 12;73:30-7. doi: 10.1016/j.ejmech.2013.12.003. Epub 2013 Dec 16.

PMID:
24378707

Supplemental Content

Support Center